{"id":38175,"date":"2025-01-28T13:29:07","date_gmt":"2025-01-28T12:29:07","guid":{"rendered":"https:\/\/www.resist-cluster.de\/?p=38175"},"modified":"2025-01-30T12:16:56","modified_gmt":"2025-01-30T11:16:56","slug":"treating-infections-beyond-antibiotics","status":"publish","type":"post","link":"https:\/\/www.resist-cluster.de\/en\/treating-infections-beyond-antibiotics\/","title":{"rendered":"Treating infections beyond antibiotics"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1352px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1 bgs-blocksatz\"><p>Ubiquitins play an important role in bacterial infections because they are important regulators of the immune response. Could these proteins be a new approach for therapies? Prof. Schl\u00fcter is investigating this question. In his RESIST project B12, he and his team are investigating the structures and functions of deubiquitinases \u2013 the enzymes that attach ubiquitins to proteins or cleave them from proteins. \u201cA therapeutic influence on ubiquitination may make it possible to treat infections beyond antibiotics,\u201d says Prof. Schl\u00fcter. Therapeutics could alter ubiquitination and thus strengthen the antibacterial immune response.<\/p>\n<p>Prof. Schl\u00fcter&#8217;s team, in collaboration with Prof. Werfel and PD Dr. R\u00f6sner, also investigated the role of ubiquitin in patients with atopic dermatitis and a Staphylococcus aureus infection. In atopic dermatitis (AD), the skin is often colonized by these bacteria, which contributes to the severity of the disease. The researchers found that the deubiquitinating enzyme CYLD is produced at higher levels in the macrophages of patients. This affects the macrophages to such an extent that they are less able to control the bacteria. The research team published the results <a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2025.1507989\/full\" target=\"_blank\" rel=\"noopener\">Ablation of the deubiquitinating enzyme cylindromatosis (CYLD) augments STAT1-mediated M1 macrophage polarization and fosters Staphylococcus aureus control<\/a> in the journal Frontiers in Immunology.<\/p>\n<p><strong>The figure shows<\/strong> <em>Staphylococcus aureus<\/em> (ultrathin section in a transmission electron microscope).<br \/>\nSource: : P. Kaiser. Coloring: A. Schnartendorff\/RKI<\/p>\n<\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:30px;width:100%;\"><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat button-xlarge button-default fusion-button-default button-1 fusion-button-default-span fusion-button-default-type buttonstapel-mitte\" target=\"_self\" title=\"Mehr Informationen\" aria-label=\"Mehr Informationen\" href=\"https:\/\/www.resist-cluster.de\/en\/research\/project-area-b\/project-b12\/\"><span class=\"fusion-button-text\">More information about the RESIST project B12<\/span><\/a><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The enzyme CYLD impairs macrophages insofar as they are less able to control bacteria. Image source: Robert Koch Institute. Image Source: Robert Koch Institute<\/p>\n","protected":false},"author":4,"featured_media":38182,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[51],"tags":[],"class_list":["post-38175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts\/38175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/comments?post=38175"}],"version-history":[{"count":6,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts\/38175\/revisions"}],"predecessor-version":[{"id":38410,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/posts\/38175\/revisions\/38410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/media\/38182"}],"wp:attachment":[{"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/media?parent=38175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/categories?post=38175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.resist-cluster.de\/en\/wp-json\/wp\/v2\/tags?post=38175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}